Sonova Holding AG

BATS-CHIXE:SOONz Stock Report

Market Cap: CHF 18.6b

Sonova Holding Valuation

Is SOONz undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SOONz when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SOONz (CHF312.15) is trading below our estimate of fair value (CHF429.11)

Significantly Below Fair Value: SOONz is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SOONz?

Key metric: As SOONz is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SOONz. This is calculated by dividing SOONz's market cap by their current earnings.
What is SOONz's PE Ratio?
PE Ratio32.9x
EarningsCHF 564.70m
Market CapCHF 18.60b

Price to Earnings Ratio vs Peers

How does SOONz's PE Ratio compare to its peers?

The above table shows the PE ratio for SOONz vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.6x
SN. Smith & Nephew
35.4x22.5%UK£8.6b
NIOX NIOX Group
23.2x17.1%UK£255.5m
CTEC ConvaTec Group
39.5x20.5%UK£4.8b
EKF EKF Diagnostics Holdings
24.4xn/aUK£116.6m
SOONZ Sonova Holding
26.6x10.7%CHF 16.0b

Price-To-Earnings vs Peers: SOONz is expensive based on its Price-To-Earnings Ratio (32.9x) compared to the peer average (30.6x).

Price to Earnings Ratio vs Industry

How does SOONz's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SOONz is expensive based on its Price-To-Earnings Ratio (32.9x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is SOONz's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SOONz PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio32.9x
Fair PE Ratio36.6x

Price-To-Earnings vs Fair Ratio: SOONz is good value based on its Price-To-Earnings Ratio (32.9x) compared to the estimated Fair Price-To-Earnings Ratio (36.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SOONz forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 312.15
CHF 296.28
-5.1%
14.1%CHF 375.00CHF 224.00n/a18
Nov ’25CHF 321.70
CHF 292.78
-9.0%
12.4%CHF 350.00CHF 227.00n/a18
Oct ’25CHF 300.60
CHF 287.53
-4.3%
11.3%CHF 345.00CHF 227.00n/a17
Sep ’25CHF 296.80
CHF 286.06
-3.6%
11.0%CHF 335.00CHF 227.00n/a17
Aug ’25CHF 268.60
CHF 284.82
+6.0%
11.8%CHF 335.00CHF 220.00n/a17
Jul ’25CHF 280.10
CHF 284.82
+1.7%
11.8%CHF 335.00CHF 220.00n/a17
Jun ’25CHF 285.30
CHF 279.12
-2.2%
12.6%CHF 335.00CHF 220.00n/a17
May ’25CHF 256.10
CHF 270.29
+5.5%
11.4%CHF 325.00CHF 200.00n/a17
Apr ’25CHF 260.90
CHF 270.65
+3.7%
12.0%CHF 325.00CHF 200.00n/a17
Mar ’25CHF 276.00
CHF 270.59
-2.0%
13.4%CHF 325.00CHF 200.00n/a17
Feb ’25CHF 279.00
CHF 267.06
-4.3%
14.7%CHF 325.00CHF 200.00n/a16
Jan ’25CHF 274.00
CHF 257.07
-6.2%
12.7%CHF 320.00CHF 200.00n/a15
Dec ’24CHF 255.60
CHF 259.75
+1.6%
13.4%CHF 340.00CHF 200.00n/a16
Nov ’24CHF 217.40
CHF 249.50
+14.8%
15.8%CHF 340.00CHF 195.00CHF 321.7016
Oct ’24CHF 217.70
CHF 252.81
+16.1%
16.3%CHF 340.00CHF 195.00CHF 300.6016
Sep ’24CHF 233.00
CHF 253.59
+8.8%
15.4%CHF 331.00CHF 195.00CHF 296.8017
Aug ’24CHF 242.70
CHF 253.59
+4.5%
15.4%CHF 331.00CHF 195.00CHF 268.6017
Jul ’24CHF 238.70
CHF 254.76
+6.7%
14.8%CHF 331.00CHF 195.00CHF 280.1017
Jun ’24CHF 234.60
CHF 248.91
+6.1%
14.6%CHF 320.00CHF 180.30CHF 285.3018
May ’24CHF 282.30
CHF 257.58
-8.8%
15.1%CHF 330.00CHF 180.30CHF 256.1016
Apr ’24CHF 268.60
CHF 257.33
-4.2%
15.2%CHF 330.00CHF 180.30CHF 260.9016
Mar ’24CHF 231.10
CHF 258.71
+11.9%
15.4%CHF 330.00CHF 180.30CHF 276.0016
Feb ’24CHF 233.00
CHF 258.71
+11.0%
15.4%CHF 330.00CHF 180.30CHF 279.0016
Jan ’24CHF 219.40
CHF 286.21
+30.4%
20.7%CHF 450.00CHF 180.30CHF 274.0016
Dec ’23CHF 248.50
CHF 291.29
+17.2%
20.0%CHF 450.00CHF 180.30CHF 255.6015
Nov ’23CHF 234.50
CHF 305.21
+30.2%
16.9%CHF 450.00CHF 255.00CHF 217.4014

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$401.70

7D

-0.06%

1Y

-16.0%

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

0HVB

US$60.47

7D

5.2%

1Y

-18.4%

Kooth

UK£60.0m

Provides digital mental health services to children, young people, and adults in the United Kingdom.

KOO

UK£1.65

7D

1.5%

1Y

-45.2%